The role of dopamine D3 receptors in the mechanism of action of cariprazine
- PMID: 31010452
- DOI: 10.1017/S109285291900083X
The role of dopamine D3 receptors in the mechanism of action of cariprazine
Abstract
Cariprazine is a new atypical antipsychotic drug (APD) with a unique pharmacodynamic profile, different from both typical and atypical APDs. Specifically, cariprazine acts as a partial agonist at the dopamine (DA) D2 and D3 receptors and serotonin 5-HT1A receptors, and as an antagonist at the 5-HT2B receptors. Moreover, it shows moderate affinities for adrenergic, histaminergic, and cholinergic receptors that are involved in mediating the side effects characteristic of typical APDs. In this review, we discuss the contribution of DA D3 receptors (D3Rs) in the etiology and pathophysiology of schizophrenia and the potential benefits that may be associated with a more selective targeting of D3R by APDs, as compared to other dopaminergic and non-dopaminergic receptor subtypes. Cariprazine, by acting on D3Rs, ameliorates anhedonia and cognitive deficits in animal models based on environmental or pharmacological manipulation. The reviewed results support the potential benefits of cariprazine in treating negative symptoms and cognitive deficits of schizophrenia, and therefore representing a promising approach in addressing the unmet clinical needs for the improved treatment of this serious neuropsychiatric disorder.
Keywords: Dopamine D3 receptors; antipsychotic drugs; cariprazine; cognitive deficits; negative symptoms; schizophrenia.
Similar articles
-
Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.Clin Schizophr Relat Psychoses. 2016 Summer;10(2):109-19. doi: 10.3371/1935-1232-10.2.109. Clin Schizophr Relat Psychoses. 2016. PMID: 27440212 Review.
-
Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine.Drug Des Devel Ther. 2019 Sep 16;13:3229-3248. doi: 10.2147/DDDT.S188760. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31571826 Free PMC article.
-
Mechanism of action of cariprazine.CNS Spectr. 2016 Apr;21(2):123-7. doi: 10.1017/S1092852916000043. Epub 2016 Mar 9. CNS Spectr. 2016. PMID: 26956157
-
Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.Psychopharmacology (Berl). 2016 Oct;233(19-20):3503-12. doi: 10.1007/s00213-016-4382-y. Epub 2016 Aug 15. Psychopharmacology (Berl). 2016. PMID: 27525990 Free PMC article.
-
Mini Review on Cariprazine: A Promising Antipsychotic Agent.CNS Neurol Disord Drug Targets. 2023;22(2):226-236. doi: 10.2174/1871527321666220324121935. CNS Neurol Disord Drug Targets. 2023. PMID: 35331126 Review.
Cited by
-
Dopaminergic neuromodulation of prefrontal cortex activity requires the NMDA receptor coagonist d-serine.Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):e2023750118. doi: 10.1073/pnas.2023750118. Proc Natl Acad Sci U S A. 2021. PMID: 34083436 Free PMC article.
-
Relevance of interactions between dopamine and glutamate neurotransmission in schizophrenia.Mol Psychiatry. 2022 Sep;27(9):3583-3591. doi: 10.1038/s41380-022-01649-w. Epub 2022 Jun 10. Mol Psychiatry. 2022. PMID: 35681081 Free PMC article. Review.
-
Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments - A Series of Two Cases.Neuropsychiatr Dis Treat. 2021 Apr 15;17:1089-1093. doi: 10.2147/NDT.S303817. eCollection 2021. Neuropsychiatr Dis Treat. 2021. PMID: 33883898 Free PMC article.
-
Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment.Front Psychiatry. 2022 Feb 10;12:825532. doi: 10.3389/fpsyt.2021.825532. eCollection 2021. Front Psychiatry. 2022. PMID: 35222108 Free PMC article.
-
Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments.Pharmaceuticals (Basel). 2020 Nov 5;13(11):365. doi: 10.3390/ph13110365. Pharmaceuticals (Basel). 2020. PMID: 33167370 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical